METHOD OF HSV PROPHYLAXIS

Abstract: Herpes virus infection can be prevented by the topical application of metallo-organic cobalt compounds according to formula (I) to the site of infection, wherein each A may be the same or different and is an alkyl group, a phenyl group or a substituted derivative of a phenyl group; wherein each Y may be the same or different and is hydrogen, an unbranched alkyl group, a halide or a group having the structure of formula (a) wherein R is hydrogen, an alkoxide group, and alkyl group, or OH; wherein each B may be the same or different and each is hydrogen or an alkyl group; wherein each X may be the same or different and each is a water soluble group having weak to intermediate ligand filed strength; and Z<-> is a soluble, pharmaceutically acceptable negative ion. Metallo-organic cobalt compounds may also be used to disinfect liquids which contain herpes virus.

Description: METHOD OF HSV PROPHYLAXIS BACKGROUND OF THE INVENTION The present invention relates to metallo-organic cobalt compounds and their use in the prophylactic treatment of subjects to prevent herpes virus infections. It has been discovered that certain conditions and diseases, e.g., inflammation, burns, wounds, and diseases caused by bacteria and fungi in mammalian species can be treated with certain complexes of cobalt having the structure: I. wherein each A may be the same or different and is an alkyl group, a phenyl group or a substituted derivative of a phenyl group; wherein each Y may be the same or different and is hydrogen, an unbranched alkyl group, a halide or a group having the structure R f, wherein R is hydrogen, an o alkoxide group, and alkyl group, or OH; wherein each B may be the same or different and each is hydrogen or an alkyl group; wherein each X may be the same or different and each is a water soluble group having weak to intermediate ligand filed strength; and Z ~ is a soluble, pharmaceutically acceptable negative ion. U. S. Patent 5,142,076, discloses the use of the foregoing described compounds as treatment for viral diseases. Today, virus infections are known to be significant causes of morbidity and mortality in human and veterinary medicine. Many of these diseases are untreatable or the available therapies are not entirely satisfactory and only provide minimal clinical response. New prophylactic treatments would decrease the incidence of these diseases and improve overall health. SUMMARY OF THE INVENTION I have discovered a prophylactic use for the series of compounds having the structure: II. wherein each A may be the same or different and is an alkyl group, a phenyl group or a substituted derivative of a phenyl group; each Y may be the same or different and is hydrogen, an unbranched alkyl group, a halide or a group having the structure R f, wherein R is o hydrogen, an alkoxide group, an alkyl group, or OH; each B may be the same or different and each is hydrogen or an alkyl group; Tr is a soluble, pharmaceutically acceptable negative ion; and each X may be the same or different and is an axial ligand selected from the wherein R 1 , R 2 , R 3 , and R 4 may be the same or different and maybe hydrogen or lower alkyl having from 1 to 4 carbon atoms; and wherein R 5 , R 6 , R 7 , R 8 and R 9 may be the same or different and may be selected from the group consisting of electron donating groups and electron withdrawing groups, with the proviso that R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 , are of a sufficiently small size so as not to prohibit the attachment of the axial ligand to the Co atom due to steric hindrance. As used herein, the term "axial" when used in conjunction with the term "ligand" refers to the fact that the ligand is oriented outside the plane of the molecule and has the same meaning as described in connection with Figure 1 of U.S. Patent No. 5,049,557. As used herein, and unless otherwise indicated, an alkyl group means a linear, branched or cyclic alkyl group containing from one to six carbon atoms. The compounds having the structure of Formula II exhibit prophylactic efficacy when applied as a topical composition to the contact site prior to contact with herpes virus, and/or by inactivating herpes virus exposed to the composition. The compositions of the invention may further be used for antisepsis or disinfection of surfaces, such as, surgical tools or preparation, such as, media or blood-derived products. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a graph depicting a study of the prophylactic properties of topical application of compounds having the structure of Formula II and comparison compounds. DETAILED DESCRIPTION OF THE INVENTION The compounds used in the present invention may be crystallized with numerous counter-anions. Counter-anions which are pharmaceutically acceptable and are water soluble, such as, halide ions, PF 6 ~ and BF 4 ~ , are preferred. The bromide and chloride salts of the present compounds are the most preferred because they are more water soluble than other salts of the compounds. As discussed above, A may be an alkyl group, a phenyl group or a substituted derivative of a phenyl group. Preferably, the alkyl group is a C r C 5 group with methyl, ethyl, and butyl groups being particularly preferred. Suitable substituted derivatives of the phenyl group are derivatives wherein each substituent is a halide, an alkyl group or a group having the structure R f, where R is o hydrogen, an alkoxide group, an alkyl group or an OH group. To date, the most useful derivatives have proven to be those in which the substituents are halides, or alkyl groups. Y may be hydrogen, an unbranched alkyl group, a halide or a group having the structure R f, wherein R is hydrogen, an alkoxide group, an alkyl o group, or an OH group. In certain embodiments, it is preferred that Y is chlorine, hydrogen atom or a C r C 3 alkyl group. In embodiments where Y has a structure R , , it is preferred that R is hydrogen a methyl group, or an OH group, o B may be hydrogen or an alkyl group, and preferably is a C r C 3 alkyl group. X may be imidazole or pyridinyl groups linked to the cobalt atom through a nitrogen of the ring. The imidazole or pyridinyl nuclei may have hydrogen atoms, or electron donating or withdrawing groups substituted thereon. The electron withdrawing or donating groups which may constitute appendant groups R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are those known in the art to exert the specified electron withdrawing or donating effects on aromatic nuclei. Typical of electron donating groups are NO 2 ~ , Cl ~ , Br ~ , and the like. The identity of the particular group is not crucial so long as it does not impart properties to the molecule which are detrimental to the desired properties of the compound, e.g., decreased antiviral activity, increased toxicity, and the like. Additionally, the group must not be so large as to prevent the axial ligand to attach to the cobalt atom due to steric effects, e.g. , steric hindrance. Preferably, the groups attached to the imidazole nucleus are alkyl having from one to three carbon atoms. Of these, methyl and ethyl are most preferred. Preferred are the unsubstituted, 2-methyl, 4-methyl, and 2-ethyl imidazoles and the unsubstituted pyridinyl. The following Table provides the structures of preferred compounds in accordance with the present invention. Compound 23, disclosed in the U. S. Patent 5,142,076 as exhibiting antiviral activity, is included as a comparison in the examples that follow. In the following diagram, B is, in each case, methyl, and A, Y, X and 2X refer to those symbols as used in structure II. The compositions used in the instant invention comprise a pharmaceutically acceptable carrier and a compound as defined above in a herpes virus prophylactic effective amount. As used herein, the expressions herpes virus prophylactic effective amount, dosage or regimen means that amount, dosage or regimen which results in a sufficient concentration of the particular compound at an appropriate site to prevent herpes virus disease. By appropriate site, it is meant a site which potentially contains herpes virus or is an area of a subject of potential exposure to herpes virus disease or is an area of a subject that has been exposed to herpes virus disease but as a result of such exposure, the subject has not yet acquired herpes virus disease. As used herein, the expression acquired herpes virus disease means that the subject, in fact, has the disease and can no longer be treated prophylactically to prevent the disease and must be treated therapeutically to ameliorate the disease. The compounds and compositions may be used in preventing infections caused by a variety of herpes viruses. Certain compounds within the group may exhibit greater efficacy against specified herpes viruses as compared with other compounds within the inventive group. Accordingly, the present invention includes the inventive compositions wherein the composition contains a compound as defined hereinabove in a prophylactic amount which is effective against the specific herpes virus. Known viruses of clinical significance are disclosed in PDR Medical Dictionarv. 1st Edition, Williams & Wilkins, pp. 1939-1947, (1995); Virology. B.N. Fields, D.M. Knipe, P.M. Howley, R.M. Chanock, J.L. Melnick, T.P. Monath, B. Roizman and S.E. Straus, Lippincott-Raven Press, N.Y. (1996). See also Antiviral Agents and Viral Diseases of Man. George J. Galasso, Richard J. Whitley, and Thomas C. Merigan, Ed., 4 th Edition, Lippincott-Raven Press, N.Y. (1997). The compounds are particularly effective against, ter alia, HSV-1, HSV-2, CMV, VZV, HHV-6, EBV, and the like. For topical administration, the inventive composition may be placed in a pharmaceutically acceptable saline solution, ointment, salve, cream or the like. The compounds used in the present invention are water soluble, although the degree of solubility may vary from compound to compound, and may be dissolved in a number of conventional pharmaceutically acceptable carriers. Suitable carriers include polar, protic solvents, such as, water, or normal saline. The compounds may also be suspended in a suspension medium that is not miscible with water, for example, petrolatum. When the compounds of formula II are to be administered by the topical route for prevention of infection, i.e. , prophylaxis or disinfection, their concentration in the saline, ointment, salve, creme, or the like can vary from about 0.00005 to about 5% by weight. A preferred concentration range lies between about 0.0005 and about 2% by weight. Typically, the topical composition shows prophylactic effect when applied to the contact site from about 1 hour before contact with the virus to about 6 hours after contact with the virus. Preferably, the topical composition is applied within five minutes of contact with the herpes virus. Particularly, the inventive compositions can be applied intravaginally for the prevention of sexually transmitted diseases. The topical composition containing the inventive compound could, for example, be coated on a condom or other sexual barrier device. When the compounds of formula II are to be used for disinfecting liquid preparations, such as, media, blood-derived products or the like, their concentration in the liquid preparations is from about 0.00005 to about 5% by weight. A preferred concentration range lies between about 0.005% and about 2% by weight. A most preferred concentration range lies between about 0.01 % and about 2% by weight. General methods for the synthesis of the compounds of the present invention are described in U.S. Patent No. 5,049,557, referred to and incorporated by reference hereinabove. As noted therein, the reaction of Co(II) complexes with molar oxygen has been studied extensively (see, R.S. Drago and B. R. Corden, Ace. Chem. Res., 1980, 13, 353 & E. C. Niederhoffer, J. H. Timmons and A.E. Martell, Chem. Rev. 1984, 84, 137). Normally, cobalt (II) forms 2: 1 peroxo bridged complexes in aqueous solutions (see E. C. Niederhoffer, J.H. Timmons and A. E. Martell, Chem. Rev. 1984, 84, 137). In recent years, a number of Co(II) complexes have been reported to give 1:1 cobalt-oxygen adducts at room temperature. These complexes usually contain ligands which when bound to Co(II) give rise to a low spin planar geometry. Addition of base and O 2 to these complexes leads to the formation of octahedral complexes where the base and the O 2 occupy axial positions (see, A. Summerville, R.D. Jones, B.M. Hoffman and F. Basolo, J.Chem. Educ, 1979, 56, 3, 157). On the basis of measurements utilizing a variety of physical techniques, it is now a well-accepted fact that the most accurate electronic structure description of the Co:O 2 moiety is a Co(III) ion bound to O 2 ~ , where the actual amount of Co - O 2 electron transfer depends on the nature of the ligand and the donor set (see, A. summerville, R. D. Jones, B.M. Hoffman and F. Basolo, J. Chem. Educ. 1979, 56, 3 157, & D. Getz, E. Malmud, B. L. Silver and Z. Dori, J. Am Chem. Soc, 1975, 97, 3846). It has been shown that electron transfer increases with increase of the ligand field strength (see, R. S. Drago and B. R. Corden, Ace. Chem. Res., 1980, 13, 353). This can be easily understood from the molecular orbital diagram depicted in Fig. 1 of U. S. Patent 5,049,557 and the description therein. The following examples illustrate the present invention. The methods used in the examples are described in the following references: For in vivo activity and toxicity of antiviral drugs for herpes viruses, see Antiviral Agents and Viral Diseases of Man, supra. In particular, Chapter 3, Preclinical Evaluation of Antiviral Agents; In vitro and Animal Model Testing by Dr. Earl R. Kern; and Chapter 6, Major Ocular Viral Infections by Dr. Deborah Paran- Langston. EXAMPLE 1 In vitro Assays With HSV-1 Virus In vitro asays were carried out to determine the direct virucidal efficacy of the compound to be tested, the potential toxicity of the compound and the intracellular anti-viral activity. The tests were carried out as follows: A. Viral Strain Used HSV1 McKrae Strain was diluted to a final concentration of 10 5 PFU/ml in minimal essential medium (MEM). Hereinafter, this dilution is referred to as the HSV-1 suspension for convenience. B. Preparation of Solutions of Inventive Compounds to be Tested A stock solution of each compound to be tested at a concentration of 5 mg/ml was prepared. The stock solution was serially diluted in Hank's Balanced Salt Solution (HBSS) to obtain final drug concentrations of 5, 2, 1, 0.5, 0.1, 0.01, 0.001 and 0.0001 mg/ml. At the time of these experiments, certain of the compounds were observed to be insoluble at the higher concentrations. In such cases, the highest dissolved concentration that could be obtained was utilized. It was subsequently found that the insolubility was due solely to the technique used for solubilization, i.e., insufficient stirring was used. With sufficient stirring, all the compounds completely dissolved. C. Determination of Direct Virucidal Efficacy Each of the drug solutions were mixed with the HSV-1 suspension in a 1: 1 ratio. The drug and HSV-1 suspension mixture was incubated at 37°C for thirty minutes with agitation every then minutes. After the incubation, fifty microliter aliquots were overlaid onto triplicate confluent human foreskin fibroblast (HFF) cell monolayers. The inoculum was absorbed for thirty minutes and then a medium containing the appropriate drug concentration in MEM was added to the monolayers to a final volume of 0.5 mililiters per culture well. The monolayers were incubated at 37°C. The developing HSV-1 cytopathology was monitored daily for two days by inverted light microscopy. Titers were calculated by multiple regression analysis. All data is presented as the average PFU/ml reduction at 24 and/or 48 hours after inoculation. D. Controls Sham-incolulated, non-treated HFF cell monolayers were included along with the drug-treated monolayers as "cell monolayer controls" . 1. HSV-1 inoculated, non-compound treated HFF monolayers were included as "positive controls"; and 2. Sham-inoculated compound treated HFF monlayers were included to demonstrate potential "toxicity effects" of the compounds. E. Determination of Intracellular Antiviral Activity HFF cell monolayers were inoculated with the HSV-suspension prepared as above by absorption for thirty minutes at 37 °C. After absorption of the virus, the inoculum was aspirated from the cell monolayers and the HSV-1 infected monolayers were rehydrated with medium containing the appropriate concentration of the solution fo the compound by adding 500 microliters of each compound concentration to triplicate HSV-1 infected monolayers. All monolayers were incubated at 37 °C. The developing HSV-1 cytopathology was monitored daily for two days by inverted light microscopy and titers were calculated by multiple progression analysis. For the intracellular anti-viral activity, "cell monolayer controls" were obtained using sham inoculated non-treated HFF cell monolayers along with the drug treated monolayers. "Positive controls" were obtained by using HSV-1 inoculated non-CTC compound treated HFF monolayers. F. Results In the tables, the symbols have the meaning indicated: + = toxic; = no toxicity; +/- = mild toxicity; ND = not done; T = toxicity effects interfered with CPE rating; CPE = cytopathic effect. EXPERIMENT 1 Results: Cell monolayer controls No adverse HFF celluar effects were evident in these monolayers. TABLE 1. - TOXICITY EFFECTS CONTROLS TABLE 2 - VIRUCIDAL EFFICACY TABLE 3 - EFFECTIVE VIRUCIDAL CONCENTRATION The toxicity of compound 82 was determined to be one order of magnitude less than the observed toxicity of 23 and 76. The virucidal efficacy of 82 (IC 50 ) was one order of magnitude less than that observed for 23 and 76. Thus, for these compounds, it appears that a reduction in HFF cell toxicity was exchanged for virucidal efficacy. EXPERIMENT 2 Results: Cell monolayer controls No adverse HFF cellular effects were evident in these monolayers. TABLE 4. - TOXICITY EFFECTS CONTROLS TABLE 5. - VIRUCIDAL EFFICACY TABLE 6. - EFFECTIVE VIRUCIDAL CONCENTRATION Compound 96 was insoluble at 10 mg/ml. A stock solution at a concentration of 1 mg/ml was moderately insoluble. As noted above, it was later discovered that this insolubility was due to insufficient stirring. However, a lack of toxicity of 96 was evident at 1 mg/ml and the antiviral activity was similar to that observed for 23. EXPERIMENT 3 Results: Cell monolayer controls No adverse HFF cellular effects were evident in these monolayers TABLE 7. TOXICITY EFFECTS CONTROLS TABLE 8 - VIRUCIDAL EFFICACY EXPERIMENT 4 Cell monolayer controls No adverse HFF cellular effects were evident in these monolayers. Antiviral Efficacy of the compounds in vitro. TABLE 9 - VIRUCIDAL EFFICACY (24 Hours PI) Non-treated = — 110f>5-6 TABLE 10 - TOXICITY EFFECTS CONTROLS TABLE 11. EFFECTIVE VIRUCIDAL CONCENTRATION The intracellular antiviral activity of the compounds is at least one log higher than the virucidal activity. This indicates that the inventive compounds have a direct virucidal effect on the HSV-1 in addition to having an intracellular effect on the HSV-1. The intracellular effect appears to be non-specific and time dependent. EXPERIMENT 5 TABLE 12 - VIRUCIDAL EFFICACY Non-treated = IO 5 TABLE 13 - TOXICITY EFFECTS CONTROL TABLE 14 - EFFECTIVE VIRUCIDAL CONCENTRATION The IC 50 and IC^ drug levels are calculated based upon the reduction in HSV titer compared to the non-drug treated control monolayers. As was observed previously, reduction in toxicity resulted in a reduction in efficacy. EXPERIMENT 6 Cell monolayer controls No adverse HFF cellular effects were evident in these monolayers. TABLE 15 - TOXICITY EFFECTS CONTROLS TABLE 16 - VIRUCIDAL EFFICACY (24 Hours PI) Non-treated = IO 4 TABLE 17 - EFFECTIVE VIRUCIDAL CONCENTRATION The IC 50 drug level was calculated based upon the reduction in HSV titer compared to the non-drug treated control monolayers. Reduction in toxicity (e.g. 93 and 96) resulted in a reduction in efficacyof the compounds in this virucidal assay. The toxicity observed with 93 and 96 was demonstrated again. The toxicity appears to be more pronounced in the 0.5 and the 0.1 mg/ml concentrations. The toxicity was evident as cell rounding, detaching from the monolayer, increased granularity and loss of normal morphology. At concentrations below the 0.5 and 0.1 mg/ml, the cell monolayers appeared (visually) to be normal with no overt toxic effects. EXPERIMENT 7 TABLE 18 - ANTIVIRAL EFFICACY Non-treated = IO 5 TABLE 19 - EFFECTIVE VIRUCIDAL CONCENTRATION Intracellular antiviral activity of the compounds is a minimum of one log higher than the virucidal activity. EXAMPLE 2 A. VIRUS USED VZV was grown to a CPE level in vitro assays with VZV of 3-4+ on HFF cell monolayers. The VZV was scraped from the flask, centrifuged and the cell pellet was resuspended in 10 ml of complete medium. 100 to 200 μl of the VZV cell associated inoculum was inoculated onto confluent HFF cell monolayers by absorption for 60 minutes at 37°C. After absorption of the virus, the inoculum was aspirated from the cell monolayers. B. PREPARATION OF SOLUTIONS TO BE TESTED Concentrations of compounds 93, 96, and 23 were prepared as follows: A stock solution of each compound at a concentration of 5 mg/ml was made. This stock solution was serially diluted in Hank's Balanced Salt Solution to obtain final drug concentrations of: 5, 2, 1, 0.5, 0.1, 0.01, 0.001, and 0.0001 mg/ml. 500 μl of each drug concentration were added to triplicate infected monolayers. (Compound 93 was observed not to be soluble at 5 and 2 mg/ml concentrations. The highest concentration of this compound used in these assays was 1 mg/ml. As explained earlier, this was due to insufficient stirring.) C. INOCULATION AND ANALYSIS The VZV-infected monolayers were rehydrated with medium containing the appropriate concentrations of compounds to be tested. All monolayers were incubated at 37 °C. Development of VZV cytopathology was monitored daily for 7 days by inverted light microscopy. Titers were calculated by multiple regression analysis. CONTROLS Sham-inoculated, non-treated HFF cell monolayers were included among with the drug-treated monolayers as cell monolayer controls. VZV inoculated, non-treated HFF monolayers were included as positive controls. RESULTS Cell monolayer controls No adverse HFF cellular effects were evident in these monolayers. TABLE 20 - VIRUCIDAL EFFICACY Non-treated = IO 4 *) This toxicity observation is questionable. TABLE 21- EFFECTIVE VIRUCIDAL CONCENTRATION Figure 1 shows the effects of Compound 96 on survival in a mouse genital HSV-2 model. Mice received one treatment of intravaginal saline (placebo), 2% Acyclovir, 0.5% Compound 96, or 2% Compound 96 as shown, just prior to infection. EXAMPLE 3 A series of studies were carried out to compare the activity of inventive antiviral Compounds 23, 76, and 82 in a primary genital HSV-2 infection of guinea pigs. The experiments were placebo-controlled and uninfected animals were treated with three concentrations of each of the preparations to assess skin irritation and determine the maximum tolerated dose. General HSV-2 Infection of Guinea Pigs A. Determination of Maximum Tolerated Dose Groups of three uninfected animals were treated topically (0.1 ml intravaginally + 0.1 ml on the external genital skin) three times daily (approximately every eight hours) for seven days with concentrations of 20, 10 or 5 mg/ml of each compound to assess any skin irritation or visible toxicity. B. Virus and Viral Inoculation The MS strain of HSV-2 was utilized for the experimental animal infection. Female Hartley strain guinea pigs (Charles River Breeding Laboratories, Kingston, NY) weighing 250-300 g were inoculated intravaginally with 1.4 x 10 5 plaque forming units of HSV-2 one hour after being swabbed for the removal of vaginal secretions. C. Treatment of Guinea Pigs Groups of 10 infected guinea pigs were treated topically as stated above with 20 mg/ml (the maximum tolerated dose) of each compound beginning 6 hours or 24 hours after inoculation with HSV-2. D. Sample Collection and Virus Assays To determine the effect of treatment on vaginal virus replication, swabs of vaginal secretions were obtained on days 1, 3, 5, 7, and 10 after HSV-2 inoculation, placed in a tube containing 2.0 ml of media, vortexed and frozen at -70° until titrated for HSV-2. When all samples were collected, they were thawed, diluted serially and HSV-2 titers were determined using rabbit kidney cells in a microtiter CPE assay. Mean peak virus titers and areas under the virus titer-day curves were calculated and analyzed. E. Scoring of External Genital Lesions To determine the effect of therapy on the development and spread of external genital lesions, lesion severity was scored on a 0 -5 + scale through the primary infection (21 days). Mean peak lesion scores and the areas under the lesion score-day curves were calculated and analyzed. F. Evaluation of Efficacy The number of animals infected over the number inoculated, lesion score-day areas and virus titer-day areas under the curve, peak lesion scores and peak virus titers between untreated and placebo-treated or placebo-treated and drug- treated animals were compared using the Mann- Whitney U rank sum test. A p-value of 0.05 or less was considered significant. RESULTS Effect of Treatment with Compound 23, Compound 76 or Compound 82 on Skin Irritation Groups of 3 guinea pigs were treated with 20, 10 or 5 mg/ml of Compound 23, Compound 76 or Compound 82 as described previously. No visible signs of any skin irritation or genital toxicity with the three compounds at these concentrations were observed. The animals remained healthy and normal in appearance throughout the study. Effect of Treatment with Compound 23, Compound 76 or Compound 82 on Vaginal Virus Replication After HSV-2 inoculation, viral replication in the vaginal tract reaches a peak on days 3-5, then declines gradually with most animals having cleared the virus by day 10. Evaluation of therapy with topical Compound 23, Compound 76, and Compound 82 on vaginal virus titers is summarized in Table 24. Early treatment with all three compounds reduced the number of animals that became infected with HSV-2 (had virus isolated on at least one swab day). Animals that received Compound 23, Compound 76 or Compound 82 beginning 6 hours after infection had an infectivity rate of 50% . In all other groups, all animals (100%) inoculated became infected. The animals treated with placebo initiated 6 hours or 24 hours after viral inoculation had virus titer-day areas under the curve (AUC) values and mean peak virus titers that were similar to the untreated control group. The virus titer-day AUC values in animals that received the Compound 23, Compound 76 or Compound 82 beginning 6 hours post-inoculation were reduced significantly when compared to the placebo-treated group (P- values of < 0.001). Treatment with these compounds at +6hr also significantly decreased the mean peak virus titers compared with the placebo-treated animals (P-values of < 0.001). Therapy with Compound 23 or Compound 76 beginning 24 hr afer viral inoculation also reduced the virus titer AUC (P-values of < 0.05). Treatment with Compound 82 at +24 hr failed to alter the virus titer AUC and none of the compounds reduced the mean peak virus titer when given at +24 hr. Effect of Treatment with Compound 23, Compound 76 or Compound 82 on Lesion Development Three to four days after HSV-2 inoculation, vesicular lesions begin to appear on the external genital skin. Lesions progress to an ulcerative stage by days 7 - 8 and gradually heal by days 15-21. Evaluation of topical Compound 23, Compound 76, and Compound 82 therapy on lesion development and severity is shown in Table 25. The animals treated with the placebo at +6 hr and +24 hr had significantly increased lesion score-day AUC values when compared to the untreated control group (P-values of < 0.001). The mean peak lesion score for the placebo given at +6hr was also significantly greater than those of the untreated control animals (P-value of <0.05). Lesion development as determined by both lesion score- day AUC values and mean peak lesion scores was significantly reduced by treatment with Compound 23, Compound 76 or Compound 82 when initiated 6 hr after infection when compared to the appropriate placebo-treated animals (P-values of < 0.001). Also, Compound 76 administered + 24 hr of infection, significantly altered the lesion AUC (P-value of < 0.01), but only when compared to the + 24 hr placebo-treated group. This difference was not significant when compared to the untreated control animals. TABLE 22 EVALUATION OF TOPICAL COMPOUND 23, COMPOUND 76, AND COMPOUND 82 THERAPY ON INFECTION RATES AND VAGINAL VIRUS TITERS DURING A PRIMARY GENITAL HSV-2 INFECTION OF GUINEA PIGS Treatment with 20 mg/ml was initiated at the times indicated and was continued three times daily for seven days both topically and intravaginally. b) NS=Not Statistically significant when compared to the untreated control or appropriate placebo-treated group. TABLE 23 EVALUATION OF TOPICAL COMPOUND 23, COMPOUND 76 AND COMPOUND 82 THERAPY ON LESION DEVELOPMENT DURING A PRIMARY GENITAL HSV-2 INFECTION OF GUINEA PIGS EXAMPLE 4 A series of viral screening tests were carried out for Compounds 23 , 64, 67, 93, 96, and 102. The strucmre of compounds number 64 and 67 are set forth in U.S. Patent No. 5,049,557 at paragraphs 2 and 3 of the Experiment Details section. In particular, for Compound 64, A is phenyl, Y is hydrogen, B is methyl, Z- is chloride, and X and X' are NH 3 . For Compound 67, A is methyl, B is methyl, Y is chlorine, Z- is chloride, and X and X' are NH 3 . Compounds 23, 64 and 67 were screened for comparison purposes. The results are shown in Table 24. The following procedures were utilized for determining antiviral efficacy and toxicity. A. Preparation of Human Foreskin Fibroblast Cells Newborn human foreskin were obtained as soon as possible after circumcisions were performed and placed in minimal essential medium (MEM) containing vacomycin, fungizone, penicillin, and gentamycin, at the usual concentrations, for four hours. The medium was then removed, the foreskin minced into small pieces and washed repeatedly until red cells were no longer present. The tissue was then trypsinized using trypsin at 0.25% with continuous stirring for 15 minutes at 37°C in a CO 2 incubator. At the end of each 15 minute period, the tissue was allowed to settle to the bottom of the flask. The supernatant containing cells was poured through sterile cheesecloth into a flask containing MEM and 10% fetal bovine serum. The flask containing the medium was kept on ice through out the trypsinizing procedure. After each addition of cells, the cheesecloth was washed with a small amount of MEM containing serum. Fresh trypsin was added each time to the foreskin pieces and the procedure repeated until no more cells became available. The cell containing medium was then centrifuged at 1000 RPM at 4°C for ten minutes. The supernatant liquid was discarded and the cells resuspended in a small amount of MEM with 10% FBS. The cells were then placed in an appropriate number of 25 cm 2 tissue culture flasks. As cells became confluent and needed trypsinization, they were gradually expanded into larger flasks. The cells were kept on vancomycin and fungizone to passage four. B. Cytopathic Effect Inhibition Assay Low passage human foreskin fibroblast cells were seeded into 96 well tissue culture plates 24 hours prior to use at a cell concentration of 2.5 x IO 4 cells per ml in 0.1 ml (MEM) supplemented with 10% fetal bovine serum (FBS). The cells were then incubated for 24 hours at 37 °C in a CO 2 incubator. After incubation, the medium was removed and 100 μl of MEM containing 2% FBS was added to all but the first row. In the first row, 125 μl of experimental drug was added in triplicate wells. Medium alone was added to both cell and virus control wells. The drug in the first row of wells was then diluted serially 1:5 throughout the remaining wells by transferring 25 μl using the Cetus Liquid Handling Machine. Afer dilution of drug, 100 μl of the appropriate virus concentration was added to each well, excluding cell control wells which received 100 μl of MEM. For HSV-1 and HSV-2 assays, the virus concentration utilized was 1000 PFU's per well. For CMV and VZV assays, the virus concentration added was 2500 PFU per well. The plates were then incubated at 37° C in a CO 2 incubator for three days for HSV-1 and HSV-2, 10 days for VZV, or 14 days for CMV. After the incubation period, media was aspirated and the cells stained with a 0.1 % crystal violet solution for 30 minutes. The stain was then removed and the plates rinsed using tap water until all excess stain was removed. The plates were allowed to dry for 24 hr and then read on a Skatron Plate Reader at 620 nm. C. Plaque Reduction Assay for HSV-1 and HSV-2 Using Semi-Solid Overlay Two days prior to use, HFF cells are plated into six well plates and incubated at 37°C with 5% CO 2 and 90% humidity. On the date of assay, the drug is made up at twice the desired concentration in 2X MEM and then serially diluted 1:5 in 2X MEM using six concentrations of drug. The initial starting concentration isusually 200 μg/ml down to 0.06 μg/ml. The virus to be used is diluted in MEM containing 10% FBS to a desired concentration which will give 20 - 30 plaques per well. The media is then aspirated from the wells and 0.2 ml of virus is added to drug toxicity wells. The plates are then incubated for one hour with shaking every fifteen minutes. After the incubation period, an equal amount of 1 % agarose was added to an equal volume of each drug dilution. This will give final drug concentrations beginning with 100 μg/ml and ending with 0.03 μg/ml and a final agarose overlay concentration of 0.5% . The drug agarose mixture is applied to each well in 2 ml volume and the plates then incubated for three days, after which the cells were stained with a 1.5 % solution of neutral red. At the end of 4-6 hr incubation period, the stain is aspirated, and plaques counted using a stereomicroscope at 10X magnification. D. VZV Plaque Reduction Assay - Semi-Solid Overlay The procedure is essentially the same as for the HSV plaque assay described above with two exceptions: 1. After addition of the drug, the plates are incubated for ten days. 2. On days three and six an additional 1 ml overlay with equal amounts of 2X MEM and 1 % agarose are added. E. CMV Plaque Assay - Semi-Solid Overlay The procedure is essentially the same as for HSV analysis with the following minor changes. The agarose used for the initial overlay and the two subsequent overlays is 0.8% rather than 1 % . They assay is incubated for 14 days with the additional 1 ml overlays being applied on days four and eight. F. Plaque Reduction Assays Using Liquid Medium Overlay The procedure for the liquid overlay plaque assay is similar to that using the agarose overlay. The procedure for adding the virus is the same as for the regular plaque assay. The drugs are made up in a concentration to be used in MEM with 2% FBS. The drugs are not made up at 2X concentration as in previous assays but are made up at the desired concentration. For HSV-1 and HSV-2 assays, an antibody preparation obtained from Baxter Health Care Corporation is diluted 1:500 and added to the media that the drug is diluted in. For CMV and VZV, no antibody in the overlay is utilized. For the CMV assay, additional medium without new drug is added on day six and allowed to incubate for a total of 11 days. For VZW, additional media is added on day five and incubated for a total of eight days. At the end of the incubation period for all of the assays, the medium is removed, the cells washed and then stained with 0.1 % crystal violet solution for ten minutes. The cells are then rinsed several times to remove any excess violet and plaques enumerated using a stereomicroscope. G. Cell Proliferation Assay Twenty-four hours prior to assay, HFF cells are seeded in 6- well plates at a concentration of 2.5 x IO 4 cells per well in MEM containing 10% FBS. On the day of the assay, drugs are diluted serially in MEM containing 10% FBS at increments of 1:5 covering a range from 100 μg/ml to 0.03 μg/ml. For drugs that have to be solubilized in DMSO, control wells receie MEM containing 10% DMSO. The media from the wells is then aspirated and 2 ml of each drug concentration is then added to each well. The cells are then incubated in a CO 2 incubator at 37 °C for 72 hours. At the end of this time, the media-drug solution is removed and the cells washed. One ml of 0.25% trypsin is added to each well and incubated until the cells start to come off of the plate. The cell-media mixture is then pipetted up and down vigorously to break up the cell suspension and 0.2 ml of the mixture is added to 9.8 ml of Isoton III and counted using a Coulter Counter. Each sample is counted three times with three replicate wells per sample. H. MTT Assay for Cell Cvtotoxicitv Twenty-four hours prior to assay, HFF cells are plated into 96 well plates at a concentration of 2.5 x IO 4 cells per well. After 24 hours, the media is aspirated and 1256 microliters of drug is added to the first row of wells and then diluted serially 1:5 using the automated Cetus Liquid Handling System in a manner similar to that used in the CPE assay. The plates are then incubated in a CO 2 incubator at 37°C for seven days. At this time, each well receives 50 microliters of 1 μg/ml solution of MTT in Dulbecco 's Phosphate Buffered Saline. The plates are then incubated for an additional four hours. At this time, the media is removed and replaced with 100 μl of 0.04 N hydrochloric acid in isopropanol. After shaking briefly, the plates are then read on a plate reader at 550 nm. I. EC50 values were also determined for each of the viruses tested for known antiviral agents. The comparison compound was ACV for all viruses except for HCMV wherein DHPG was the comparison compound. In Table 24, these comparison EC50 values are indicated with an asterisk. In Table 25, the drug FIAU (2'-fluoro-5-iodo-arabinosyl-uracil) was used as a control. TABLE 24 ANTIVIRAL ACTIVITY TABLE 25 TOXICITY ASSAYS - IC 50 EXAMPLE 5 The compounds of the present invention may be prepared by the following general procedure. The cobalt-II complex is prepared by mixing equimolar amounts of the N,N'-bisethylenediimine ligands, e.g., L23 and the like as disclosed in U.S. Patent No. 5,049,557 with cobalt acetate in methanol under nitrogen. About 2.2 equivalents of the desired axial ligand is added followed by oxidation. The desired product may then be precipitated by the addition of a saturated aqueous solution of sodium chloride or sodium bromide followed by recrystallization from an ethanol-water solution. Compound 96 (having bromide as the counterion) was synthesized as follows: A 3-neck flask equipped with a nitrogen bubbler and a 2 liter dropping funnel was charged with 112 grams (0.5 moles) of the ligand (L23 or N,N'bis- (acetylacetone)ethylene-diimine) in 500 ml of absolute methanol. To the ligand solution is added 125 grams (0.5 moles) of cobalt acetate tetrahydrate dissolved in 1.5 litersof degassed methanol. The reaction mixture is stirred for 2 hours and then refluxed for 15 minutes on a hot water bath. An orange solution results to which 90 grams (1.1 moles) of 2-methyl imidazole dissolved in 100ml of methanol are added. The reaction mixture is exposed to the open air while maintaining vigorous stirring. Ten grams of activated charcoal are added to the stirring mixture and the oxidation is continued overnight. The mixture is then filtered and 50 grams of sodium bromide dissolved in a minimum amount of water is added to the filtered brown solution. The solution obtained is concentrated and allowed to crystallize. The crude product is recrystallized from hot ethanol-water solution by standing at room temperature or a lower temperature. The purity of the product is checked by elemental analysis, electronic spectra and NMR. EXAMPLE 6 In a study of the mouse model, vaginal herpes infection was completely blocked by topical application of Compound 96. Sixty female Swiss Webster mice pretreated with medroxyprogesterone acetate were randomized to four groups of 15 to receive either Saline (control), 2% Acyclovir, 2% Compound 96, or 0.5% Compound 96. Animals were anesthetized by intraperitoneal injection of sodium pentabarbital and then administered 15 l of control or test compound intravaginally in one treatment. They were then immediately challenged by intravaginal instillation with 15 μl of a suspension containing IO 4 plaque forming units HSV-2 strain 186. Vaginal swabs were collected on days 1 and 2 post-inoculation (PI) to assess the effect of treatment on vaginal replication in the genital tract. In addition, all animals were examined daily until day 21 PI for mortality and signs of infection (erythema, hair loss and hind limb paralysis). The mortality curve of the experiment is shown in Figure 1, and final outcome data in Table 26. Both the control and acyclovir groups showed high mortality, with 13/15 and 12/15 mice dying, respectively. In contrast, the Compound 96 groups all lived, and none of these animals developed any signs of genital disease. Viral replication data are also presented in Table 26. Virus was found in the genital tracts of all 15 control-treated mice, indicating that all the animals, including the two survivors, became infected. Among the mice receiving acyclovir, virus was detected in 12/15 animals, indicating that intravaginal acyclovir did not provide significant protection against infection. Mice treated with Compound 96 had no detectable virus on either day 1 or 2 PI, showing that treatment prevented virus replication at the site of inoculation. TABLE 26 a mean log 10 viral titers + SEM are averaged for infected animals only The study was repeated using a wider range of Compound 96 concentrations. The lowest concentration of 0.01 % protected 6 of 10 animals from death, while concentrations of 0.1 % or more completely protected mice from visible infection and death. The results of this smdy are presented in Table 27. TABLE 27 mean log 10 viral titers + SEM are averaged for infected animals only A smdy of the effect of the time of application relative to the time of inoculation with the virus is reported in Table 28. TABLE 28

Claims: We claim: 1. A method for preventing herpes virus infection in animals comprising topically applying a composition comprising a herpes virus prophylactic effective amount of a compound having the structure II wherein each A may be the same or different and is an alkyl group, a phenyl group or a substituted derivative of a phenyl group; Y may be the same or different and is hydrogen, an unbranched alkyl group, a halide or a group having the structure R " (j " wherein R is hydrogen, an alkoxide group, an alkyl group, or OH; B may be the same or different and each is hydrogen or an alkyl group; is a soluble, pharmaceutically acceptable negative ion, and X may be the same or different and is an axial ligand selected from the group consisting of moieties having the formula: wherein R 1 , R 2 , R 3 , and R 4 may be the same or different and may be hydrogen or lower alkyl having from 1 to 4 carbon atoms; with the proviso that R 1 , R 2 , R 3 , and R 4 are of a sufficiently small size so as not to prohibit the attachment of the axial ligand to the Co atom due to steric hindrance. 2. The method of claim 1 wherein the compound is from about 0.00005 to about 5% by weight of the composition. 3. The method of claim 1 wherein the compound is from about 0.005 to about 5% by weight of the composition. 4. The method of claim 1 wherein the compound is from about 0.005 to about 2% by weight of the composition. 5. The method of claim 1 wherein the compound is from about 0.01 to about 2% by weight of the composition. 6. The method of claim 1 wherein the composition is in the form of a pharmaceutically acceptable saline solution, ointment, salve, creme, or the like. 7. The method of claim 1 wherein the composition is applied to that site on the animal which is exposed to the herpes virus. 8. The method of claim 7 wherein the composition is applied intravaginally. 9. The method of claim 7 wherein the composition is applied from about 1 hour before to about 6 hours after exposure to the herpes virus. 10. The method of claim 7 wherein the composition is applied from about 5 minutes before to about 5 minutes after exposure to the herpes virus. 11. The method of claim 1 wherein the herpes virus is Herpes Simplex Virus-2. 12. The method of claim 1 wherein the compound is Compound 96. 13. The method of claim 1 wherein the step of topically applying the composition is performed by contacting the animal with an applicator coated with the composition. 14. The method of claim 13 wherein the applicator is a condom. 15. A method for disinfecting a liquid containing a herpes virus comprising adding a composition comprising a herpes virus prophylactic effective amount of a compound having the structure II wherein each A may be the same or different and is an alkyl group, a phenyl group or a substituted derivative of a phenyl group; Y may be the same or different and is hydrogen, an unbranched alkyl group, a halide or a group having the structure R ~ fj " wherein R is hydrogen, an 0 alkoxide group, an alkyl group, or OH; B may be the same or different and each is hydrogen or an alkyl group; Z " is a soluble, pharmaceutically acceptable negative ion, and X may be the same or different and is an axial ligand selected from the group consisting of moieties having the formula: wherein R 1 , R 2 , R 3 , and R 4 may be the same or different and may be hydrogen or lower alkyl having from 1 to 4 carbon atoms; with the proviso that R 1 , R 2 , R 3 , and R 4 are of a sufficiently small size so as not to prohibit the attachment of the axial ligand to the Co atom due to steric hindrance. 16. The method of claim 15 wherein the compound is added in an amount of about 0.00005 to about 5% by weight of the liquid. 17. The method of claim 15 wherein the compound is added in an amount of about 0.005 to about 5% by weight of the liquid. 18. The method of claim 15 wherein the compound is added in an amount of about 0.005 to about 2% by weight of the liquid. 19. The method of claim 15 wherein the compound is added in an amount of about 0.01 to about 2% by weight of the liquid. 20. The method of claim 15 wherein the liquid is a growth media or a blood-derived product.

Inventors: BOURNE NIGEL, STANBERRY LAWRENCE R, BOURNE, NIGEL, STANBERRY, LAWRENCE, R.
Applicants: CHILDRENS HOSP RES FOUNDATION, THE CHILDREN'S HOSPITAL RESEARCH FOUNDATION
Application year: 1999
Main classification: A01N55
IPC codes: A61K31